Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 6Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 5atezolizumab 3Ipilimumab 3cabozantinib 2Temozolomide 2Immunoglobulin G 2Disulfides 2Cisplatin 2Carboplatin 2pembrolizumab 1niraparib 1lutetium Lu 177 dotatate 1dostarlimab 1budigalimab 1Topotecan 1Specimen Handling 1Radiosurgery 1Magnetic Resonance Spectroscopy 1Irinotecan 1Etoposide 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1Bevacizumab 1BAY 1895344 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Neuroendocrine × budigalimab × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡